Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Details
State: Public
Version: author
Serval ID
serval:BIB_365F37D27EAF
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Journal
Expert Opinion on Investigational Drugs
ISSN
1744-7658
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
17
Number
8
Pages
1225-1235
Language
english
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural ; Review
Abstract
BACKGROUND: Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor. OBJECTIVE: To summarize the preclinical and clinical experience with cilengitide for GBM. METHODS: Preclinical studies and clinical trials evaluating cilengitide for GBM were reviewed. RESULTS/CONCLUSIONS: Cilengitide is active and synergizes with external beam radiotherapy in preclinical GBM models. In clinical trials for recurrent GBM, single-agent cilengitide has antitumor benefits and minimal toxicity. Among newly diagnosed GBM patients, single-arm studies incorporating cilengitide into standard external beam radiotherapy/temozolomide have shown encouraging activity with no increased toxicity and have led to a planned randomized Phase III trial.
Keywords
Animals, Antineoplastic Agents, Central Nervous System Neoplasms, Clinical Trials as Topic, Drug Evaluation, Preclinical, Glioblastoma, Humans, Integrins, Models, Molecular, Oligopeptides, Protein Binding, Snake Venoms, Treatment Outcome
Pubmed
Web of science
Create date
12/03/2009 14:27
Last modification date
20/08/2019 14:24